Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to assess the systemic absorption and disposition of tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset® T).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Lausanne Hospitals
• Treatments: Tobramycin

Criteria

Inclusion Criteria:

• Adult (> or =18 years old) patients

• Treatment with Osteoset® T

Exclusion Criteria:

• Intravenous tobramycin